Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in ...
Oracle is enabling businesses to automate workflows and build intelligent applications with low-code, no-code, and ...
Independent Data Monitoring Committee recommends ASPIRE continue without modification; no safety concerns identified. Fully ...
A new study finds that use of the OpenEvidence platform has soared since 2024, with early-career clinicians relying on it ...
Median overall survival of 15.9 months in Cyclin E1-positive PROC, with 1–5 prior lines of therapy; safety profile in DENALI Part 1b was ...
Zentalis Pharmaceuticals reported 15.9-month median survival in Cyclin E1-positive ovarian cancer patients treated with ...
Odyssey Therapeutics reports positive Phase 2a results for OD-001 in ulcerative colitis, indicating significant clinical efficacy and safety.
Comprehensive Real-World Claims Analysis Identifies an Estimated 154,986 Patients Diagnosed With DSAP in the U.S. WAYNE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE)-- Palvella Therapeutics, Inc. (Palvella or ...
New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates ...
Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy Data to be presented as a rapid oral presentation at ESMO ...
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania ...
- In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results